GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXT) » Definitions » LT-Debt-to-Total-Asset

LIXT (Lixte Biotechnology Holdings) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Lixte Biotechnology Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lixte Biotechnology Holdings's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Lixte Biotechnology Holdings's long-term debt to total assets ratio stayed the same from Jun. 2023 (0.00) to Jun. 2024 (0.00).


Lixte Biotechnology Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Lixte Biotechnology Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings LT-Debt-to-Total-Asset Chart

Lixte Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lixte Biotechnology Holdings Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lixte Biotechnology Holdings LT-Debt-to-Total-Asset Calculation

Lixte Biotechnology Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/4.309
=

Lixte Biotechnology Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=0/2.668
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lixte Biotechnology Holdings  (NAS:LIXT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Lixte Biotechnology Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lixte Biotechnology Holdings Business Description

Traded in Other Exchanges
N/A
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Executives
Rene Bernards director KONINGSVAREN 37, ABCOUDE P7 1391AD
Van Der Baan Bastiaan Jeroen director HOGEWEG 4-H, AMSTERDAM P7 1098CB
Eric Forman 10 percent owner 117 E. 29TH ST., APT. 5A, NEW YORK NY 10016
Regina Brown director 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Glenn Krinsky 10 percent owner C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
Robert Greenberg 10 percent owner SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266
Gil Schwartzberg 10 percent owner 269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212
Philip F Palmedo director 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
John S Kovach director, 10 percent owner, officer: Pres., CFO & Secty 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
Stephen J. Forman director 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Hung Tak Ho 10 percent owner MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000
Robert N Weingarten officer: Vice President and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
James Miser officer: Chief Medical Officer 680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101
Jane Merrill Riggs 10 percent owner 4852 SAINT ANDRES AVENUE, LA VERNE CA 91750

Lixte Biotechnology Holdings Headlines